Axsome Therapeutics(AXSM) - 2025 Q1 - Quarterly Report

Financial Performance - Total revenues for Q1 2025 were $121.463 million, a 62$74.999 million in Q1 2024[16] - Product sales, net for Q1 2025 reached $120.358 million, up from$74.096 million in the same period last year, representing a 62% growth[16] - The net loss for Q1 2025 was $59.413 million, compared to a net loss of$68.357 million in Q1 2024, reflecting a 13% improvement[16] - Operating expenses for Q1 2025 totaled $178.445 million, compared to$142.274 million in Q1 2024, marking a 25% increase[16] - The Company reported a consolidated net loss of $59.4 million for the three months ended March 31, 2025, an improvement from a net loss of$68.4 million in the same period of 2024[178] - The accumulated deficit as of March 31, 2025, was $1,182.2 million, highlighting the ongoing financial challenges faced by the company[194] Cash and Liquidity - Cash and cash equivalents as of March 31, 2025, were$300.910 million, down from $315.353 million at the end of 2024[14] - The Company expects its existing cash of$300.9 million will be sufficient to fund its operating cash requirements for at least twelve months[57] - The Company may utilize public and private equity offerings, debt financings, and strategic alliances to finance future cash needs if market conditions are favorable[32] - The Company must maintain Qualified Cash of at least $30.0 million plus the Qualified Cash A/P Amount, with conditional waivers if market capitalization exceeds$1.5 billion[115] Product Development and Sales - The company launched Symbravo® in January 2025, approved for the acute treatment of migraine, expanding its product portfolio[26] - Axsome Therapeutics has a diverse portfolio of FDA-approved treatments for CNS conditions, addressing over 150 million people in the U.S.[23] - The Company currently has three commercial products: Auvelity, Sunosi, and the recently FDA-approved Symbravo[34] - Product sales, net for Auvelity reached $96.231 million, up 80.0$53.395 million in the prior year, while Sunosi sales increased to $24.127 million from$20.701 million[157] - The company expects revenue fluctuations for Auvelity, Sunosi, and Symbravo based on demand, emphasizing the need for successful commercialization of its products[196] Research and Development - Research and development expenses for AXS-05 were $14.5 million for the three months ended March 31, 2025, compared to$13.5 million for the same period in 2024[178] - Research and development expenses for the three months ended March 31, 2025, were $44.8 million, an increase from$36.8 million in 2024, reflecting ongoing investment in product development[208] - The company expects moderate increases in research and development costs as it continues to develop current and future product candidates[212] Revenue Recognition and Accounting - Revenue is recognized when the customer obtains control of a promised good or service, reflecting the consideration expected to be received[36] - The Company generates revenue from license agreements, which may include non-refundable upfront fees and royalties on sales of products[38] - The Company recognizes revenue from product sales net of reserves for variable consideration, which reflects the best estimate of the amount entitled based on contract terms[42] - The Company estimates variable consideration for rebates, discounts, and other incentives based on expected patient usage and inventory levels[44] Debt and Financing - As of March 31, 2025, total outstanding debt was $180.0 million, with an accreted final payment fee of$4.5 million and unamortized debt discount of $3.1 million[122] - The Fifth Amendment to the Loan Agreement increased the Tranche 3 Commitment from$75.0 million to $80.0 million[109] - The aggregate principal amount under the Loan Agreement increased from$300.0 million to $350.0 million[110] Customer Concentration - The company’s three largest customers accounted for approximately 32$48.97 and an intrinsic value of $565,499[140] - The total unrecognized compensation cost related to unvested stock options was$148.8 million, expected to be recognized over a weighted average period of 2.3 years[142] - The company recorded stock-based compensation expense of $23.308 million for the three months ended March 31, 2025, compared to$20.190 million in the same period of 2024[149] Miscellaneous - The Company has not recorded any allowances for doubtful accounts receivable as of March 31, 2025, indicating no significant credit losses historically[73] - The Company has a single operating segment focused on developing therapies for CNS disorders, with financial performance assessed based on consolidated net loss[175] - The Company did not record any income tax expense for the three months ended March 31, 2025 and 2024, maintaining an effective tax rate of 0%[170]